Clinical trial · Interventional
Innovation for Standard Identification of Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cancer: Towards Development of Personalized Biomarkers in Clinical Oncology (PAIR HPV)
Innovation for Standard Identification for Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cance: Towards Development of Personalized Biomarkers in Clinical Oncology (PAIR HPV : Human PapillomaVirus)
NCT02554565CI-TRIAL-00094679PAIR HPVterminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study in competition with another so it was decided to stop recruitment
Summary
Brief summary (as posted)
Quantification and follow-up of circulating tumoral DNA in serum and/or plasma of patients with cervical cancer compared to the early detection of minimal metastatic disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sampling | Procedure | — | UNRESOLVED |
| Tumor biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Tumor biopsies and blood sampling
- interventionNames
- Procedure: Tumor biopsy
- Procedure: Blood sampling
Primary outcomes (1)
- measure
- Quantification and follow-up of circulating tumoral DNA in serum and/or plasma of patients with cervical cancer compared to the early detection of minimal metastatic disease.
- timeFrame
- Until 2 years after treatment
- description
- Detection rate of circulating tumoral DNA with confidence interval of 95% of this rate. Description of the variability of this rate according to the initial stage of the disease, treatment and disease progression.
Secondary outcomes (2)
- measure
- Validation of NGS methodology for the molecular characterization of genetic alterations related to the integration of viral DNA sequences.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient with cervical cancer, at any stage, before any anti-tumoral treatment. 2. Age ≥ 18 years. 3. Patient information and signature of the informed consent or her/his legal representative. 4. Patient having given her/his agreement for a second biopsy at diagnosis if the first one was performed outside of the center and was not cryopreserved. Exclusion Criteria: 1. Person deprived of liberty or under supervision. 2. Inability to attend scheduled follow-up visits for any psychological, sociological or geographical reasons.
References
Publications (0)
Data not yet available
No reference posted for this study.